Rapidly progressive hyperpigmented keratotic plaques with epidermotropism
How to cite this article: Taneja N, Dev T, Patel U, Arava S, Gogia A, Gupta V. Rapidly progressive hyperpigmented keratotic plaques with epidermotropism. Indian J Dermatol Venereol Leprol 2023;89:283-6.
A 47-year-old, otherwise healthy man presented with multiple hyperpigmented plaques on his trunk and extremities. The plaques were first noticed on the trunk five months back which subsequently involved the extremities. He had no systemic complaints. On cutaneous examination, we noted numerous round-to-oval hyperpigmented keratotic papules and mildly scaly plaques (size 1-5 cm) on the trunk and extremities [Figure 1a]. The truncal and lower limb plaques were larger, with some showing superficial ulceration and annular configuration [Figure 1b]. There was prominent palmoplantar involvement, with coalescing keratotic papules and plaques on the soles [Figure 1c]. Routine laboratory investigations including complete blood count, serum biochemistry and lactate dehydrogenase levels (143 U/L) were within normal limits. A punch skin biopsy was performed from keratotic plaques over the abdomen and sole.
What is your diagnosis?
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma
Skin biopsies showed irregularly acanthotic epidermis with dense diffuse pan-dermal infiltrate of lymphocytes and histiocytes. There were scattered large and atypical lymphocytes in the epidermis, present singly and in clusters forming microabscesses [Figures 2a and b]. We observed mild-to-moderate epidermal spongiosis and focal spongiotic vesicles, along with few necrotic keratinocytes [Figures 2c and d]. The lymphocytes were strongly immunopositive for CD3 and CD8 [Figure 3a], focally positive for CD4 [Figure 3b] and negative for CD20 and CD30. Peripheral blood examination and bone marrow biopsy were unremarkable. 18-fluorodeoxyglucose whole body positron emission tomography scan demonstrated metabolically active uptake limited to cutaneous and soft-tissue lesions. The patient was treated with methotrexate (15–30 mg/week) for three months, followed by all-trans-retinoic acid (80 mg/day) for a month without much improvement. Subsequently, pegylated doxorubicin (50 mg/month) was administered with partial flattening of the plaques. Six months following treatment, the disease worsened with multiple new plaques and new-onset bullous lesions and crusted erosions, with immunohistological features of aggressive epidermotropic CD8+ T-cell lymphoma. He was subsequently administered one cycle of gemcitabine (1.2 g/m2) and oral prednisolone 40 mg/day, however, COVID-19 lockdown prevented further follow-up visits. We lost the patient after three months due to worsening of skin lesions and general condition.
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma represents less than 1% of all cutaneous T-cell lymphomas and is included as a provisional entity in the latest WHO/EORTC classification.1 It was referred to as “Berti’s lymphoma,” “generalized pagetoid reticulosis,” or “Ketron-Goodman disease” before the category of primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma was established.2-4 It is characterized by rapidly progressing disseminated patches, papules, plaques, nodules and tumors with central necrosis and ulceration.4 There is a propensity for visceral metastasis to lung, testis, central nervous system and oral mucosa, but lymph nodes are often spared. However, skin-limited disease has been reported rarely, similar to our case.5 Histological features include dense dermal lymphocytic infiltrates, with marked pagetoid epidermotropism composed of pleomorphic small- to medium-sized T-cells. The neoplastic T-cells have a CD8+/CD4- cytotoxic T-cell profile with granzyme B, perforin and TIA-1 marker expression.6 Conventional therapies for cutaneous T-cell lymphomas are generally ineffective, while interferon-alpha and multiagent chemotherapy have been tried with unsatisfactory results.7,8 It has an aggressive clinical course and poor prognosis with a median survival of 12–32 months.4,7 Allogenic hematopoietic stem cell transplantation has induced partial or complete remission in few patients.4 A recent report has highlighted long-term remission with brentuximab vedotin monotherapy.9 In the absence of a standard accepted treatment for this lymphoma and skin-limited disease in our patient, we tried methotrexate initially, but later escalated to monoagent chemotherapies such as doxorubicin and gemcitabine due to inadequate response.
Apart from primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma, differential diagnoses of CD8+ lymphoproliferative disorders include CD8+ mycosis fungoides, pagetoid reticulosis, lymphomatosis papulosis type D, primary cutaneous acral CD8+ lymphoma and subcutaneous panniculitic T-cell lymphoma. Of these, CD8+ mycosis fungoides particularly can be a close differential diagnosis due to its clinical and histologic similarity (epidermotropism). Although both can present with plaques and ulcerated tumors, the verrucous or hyperkeratotic and annular morphology of plaques, accentuated palmoplantar involvement and rapid disease progression favour the diagnosis of primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. On histopathology, features such as spongiosis with spongiotic blisters, necrotic keratinocytes, deep dermal infiltrate, angio- and adnexotropism in addition to epidermotropism should raise the possibility of primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma [Table 1]. It is not unusual for these patients to be initially misdiagnosed as mycosis fungoides.4 Correct diagnosis of this aggressive lymphoma requires a strong clinicopathological correlation.
|Features||Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma||CD8+ mycosis fungoides|
|History||Short, weeks to months, rapid progression||Long, months to years|
|Course||Aggressive; rapidly fatal course with a median survival time of 12–32 months||Indolent|
|Morphology of skin lesions||Patches, plaques, verrucous or hemorrhagic papules, nodules and tumors
A few show annular plaques with peripheral erosions and central ulceration; some may show a spontaneous central resolution
|Patches, plaques and nodules|
|Distribution of skin lesions||Generalized
|Progression||No sequential progression from patches to plaques to nodules||Sequential progression from patches to plaques to nodules noted|
Spares lymph nodes
Involves lung, testes, CNS and
Rare extranodal; spreads to lung, spleen and liver
|Epidermotropism||All stages show marked epidermotropism and it usually follows a pagetoid or linear
|Less pronounced, usually present in early lesions|
|Spongiosis||Usually seen, sometimes
prominent with spongiotic vesicles
|Necrotic keratinocytes||Quite common||Rare|
|Common, with large
intraepidermal aggregates of atypical lymphocytes
|Less common and scattered microaggregates of atypical lymphocytes|
|Depth of infiltrate||Nodular or diffuse infiltrate extending to deep dermis or subcutis||Superficial dermal infiltrate|
|Adnexae||Usually involved (lymphoepithelioid pattern)||Rarely affected, seen in syringotropic and folliculotropic variants|
|Angiocentricity and angioinvasion||Relatively common||Very rare|
|Immunophenotyping||CD2–, CD4–, CD5–, CD45RO–
CD3+, CD7+, CD8+, CD45RA+
βF-1+, TIA-1+, perforin+, granzyme-B+ commonly positive
|CD4±, CD7–, CD45RA±
CD2+, CD3+, CD5+, CD8+, CD45RO+
TIA-1±, perforin±, granzyme-B± uncommon
directed treatment/low-dose methotrexate)
|Ineffective||Usually first line of treatment|
|Multiagent chemotherapy||Usually required, though not effective
Allogenic hematopoietic stem
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent.
Conflicts of interest
There are no conflicts of interest.
Financial support and sponsorship